Electrochemical Immunosensing of ST2: A Checkpoint Target in Cancer Diseases

A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of...

Full description

Saved in:
Bibliographic Details
Published in:Biosensors (Basel) 2021-06, Vol.11 (6), p.202
Main Authors: Torrente-Rodríguez, Rebeca M., Martín, Cristina Muñoz-San, Gamella, Maria, Pedrero, María, Martínez-Bosch, Neus, Navarro, Pilar, García de Frutos, Pablo, Pingarrón, José M., Campuzano, Susana
Format: Article
Language:English
Subjects:
Adenocarcinoma
Antibodies
Beads
Biomarkers
Cancer
Carboxylic acids
Diabetes
Electrical measurement
electrochemical immune platform
Electrochemistry
Electrodes
Enzyme-linked immunosorbent assay
Enzymes
human ST2
Immunoassay
Immunoconjugates
Immunosensors
Interleukin 1
Medical prognosis
Metabolism
Mortality
Pancreas
Pancreatic cancer
Peroxidase
Plasma
Selectivity
Sodium
Streptavidin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of carboxylic acid-microsized magnetic particles (HOOC-MBs) were used to selectively capture ST2. A biotinylated secondary antibody further conjugated with a streptavidin peroxidase conjugate (Strep-HRP) was used to accomplish the sandwiching of the target protein. The immune platform exhibits great selectivity and a low limit of detection (39.6 pg mL−1) for ST2, allowing the determination of soluble ST2 (sST2) in plasma samples from healthy individuals and patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in only 45 min once the immunoconjugates have been prepared. The good correlation of the obtained results with those provided by an ELISA kit performed using the same immunoreagents demonstrates the potential of the developed strategy for early diagnosis and/or prognosis of the fatal PDAC disease.
ISSN:2079-6374
2079-6374
DOI:10.3390/bios11060202